Mecanismos alternativos de transmissão do Trypanosoma cruzi no Brasil e sugestões para sua prevenção

Dias, João Carlos Pinto; Neto, Vicente Amato; Luna, Expedito José de Albuquerque

doi:10.1590/s0037-86822011005000032

Cited by 58 publications

(53 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, due to the absence of a systematic program of routine serological screening during prenatal care in endemic areas, and the fact that the majority of children with congenital transmission are clinically asymptomatic, it is difficult to estimate the actual prevalence of congenital Chagas disease in Brazil [27]. Chagas disease is emerging as an opportunistic disease, with reactivation of chronic disease in the form of meningoencephalitis and/or myocarditis, whether as an AIDS-defining condition or as an event that is associated with induced immunosuppression such as in transplants [27,29].…”

Section: Discussionmentioning

confidence: 99%

Mortality due to Chagas disease in Brazil from 1979 to 2009: trends and regional differences

Martins-Melo

Ramos

Alencar

et al. 2012

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Studies on mortality due to parasitic diseases such as Chagas disease are useful to understand the epidemiology and to plan and guide control measures for these diseases. We analyzed mortality trends due to Chagas disease in Brazil and regions, between 1979 and2009. Methodology: Mortality data (underlying cause of death) were obtained from the nationwide Mortality Information System (SIM) of the Ministry of Health. We calculated crude mortality rates and rates standardized by age, as well as proportional mortality. Results: In total, 27,560,043 deaths occurred in the study period. In 172,066 deaths, Chagas disease was mentioned as the underlying cause (proportional mortality: 0.62%). The mean crude and age-standardized mortality rates were 3.61 and 5.19 deaths/100,000 inhabitants/year, respectively. During the observation period, Chagas mortality declined significantly at the national level (R 2 =97%, p<0.001), with different patterns between regions. There was a significant reduction in mortality in the Central-West (R 2 =90%, p<0.001), Southeast (R 2 =98%, p<0.001) and South (R 2 =94%, p< 0.001), but in the North (R 2 =34%, p=0.001) and Northeast (R 2 =65%, p<0.001) regions mortality increased. Conclusions: Despite the overall decline in mortality due to Chagas disease in Brazil, it remains an important public health problem. After successful control of the primary vector Triatoma infestans, intervention measures must focus on improved access to health care and secondary prevention. The North and Northeast regions, where vectors other than T. infestans have a primary role, need special attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality due to Chagas disease in Brazil from 1979 to 2009: trends and regional differences

Martins-Melo

Ramos

Alencar

et al. 2012

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…cruzi ). It is possible to distinguish the following modes of transmission [10], [11], [12], [13]:Vectorial: The parasite is transmitted by the Triatomine vector also known as the “kissing bug”Congenital: Transmission from mother to childOral: Through the ingestion of contaminated food or drinkIatrogenic: Following contaminated blood transfusion or organ transplantation.…”

Section: Introductionmentioning

confidence: 99%

Chagas disease research and development: Is there light at the end of the tunnel?

Chatelain

2017

Computational and Structural Biotechnology Journal

130

View full text Add to dashboard Cite

Chagas disease, or American trypanosomiasis, is the result of infection by the parasite Trypanosoma cruzi. It is endemic in Latin America, and spreading around the globe due to human migration. Although it was first identified more than a century ago, only two old drugs are available for treatment and a lot of questions related to the disease progression, its pathologies, and not to mention the assessment of treatment efficacy, are subject to debate and remain to be answered. Indeed, the current status of evidence and data available does not allow any absolute statement related to treatment needs and outcome for Chagas patients to be made. Although there has been some new impetus in Research and Development for Chagas disease following recent new clinical trials, there is a scientific requirement to review and challenge the current status of evidence and define basic and clinical research priorities and next steps in the field. This should ensure that the best drugs for Chagas disease are developed, but will require a focused and collaborative effort of the entire Chagas disease research community.

show abstract

“…Currently, the transmission of this disease primarily depends on the ingestion of food contaminated with the feces of sucking Triatominae insects, although the classical transmission route through the vector still occurs in endemic areas [2,3]. Other routes such as blood transfusion, organ transplantation and congenital transmission can also occur [4]. This illness presents two phases (acute and chronic) that have distinct characteristics.…”

Section: Introductionmentioning

confidence: 99%

Differential Gel Electrophoresis (DIGE) Evaluation of Naphthoimidazoles Mode of Action: A Study in Trypanosoma cruzi Bloodstream Trypomastigotes

et al. 2016

View full text Add to dashboard Cite

BackgroundThe obligate intracellular protozoan Trypanosoma cruzi is the causative agent of Chagas disease, a neglected illness affecting millions of people in Latin America that recently entered non-endemic countries through immigration, as a consequence of globalization. The chemotherapy for this disease is based mainly on benznidazole and nifurtimox, which are very efficient nitroderivatives against the acute stage but present limited efficacy during the chronic phase. Our group has been studying the trypanocidal effects of naturally occurring quinones and their derivatives, and naphthoimidazoles derived from β-lapachone N1, N2 and N3 were the most active. To assess the molecular mechanisms of action of these compounds, we applied proteomic techniques to analyze treated bloodstream trypomastigotes, which are the clinically relevant stage of the parasite.Methodology/Principal FindingsThe approach consisted of quantification by 2D-DIGE followed by MALDI-TOF/TOF protein identification. A total of 61 differentially abundant protein spots were detected when comparing the control with each N1, N2 or N3 treatment, for 34 identified spots. Among the differentially abundant proteins were activated protein kinase C receptor, tubulin isoforms, asparagine synthetase, arginine kinase, elongation factor 2, enolase, guanine deaminase, heat shock proteins, hypothetical proteins, paraflagellar rod components, RAB GDP dissociation inhibitor, succinyl-CoA ligase, ATP synthase subunit B and methionine sulfoxide reductase.Conclusion/SignificanceOur results point to different modes of action for N1, N2 and N3, which indicate a great variety of metabolic pathways involved and allow for novel perspectives on the development of trypanocidal agents.

show abstract

Mecanismos alternativos de transmissão do Trypanosoma cruzi no Brasil e sugestões para sua prevenção

Cited by 58 publications

References 10 publications

Mortality due to Chagas disease in Brazil from 1979 to 2009: trends and regional differences

Mortality due to Chagas disease in Brazil from 1979 to 2009: trends and regional differences

Chagas disease research and development: Is there light at the end of the tunnel?

Differential Gel Electrophoresis (DIGE) Evaluation of Naphthoimidazoles Mode of Action: A Study in Trypanosoma cruzi Bloodstream Trypomastigotes

Contact Info

Product

Resources

About